ACAD EPS figures out v today. Timely release of useless headlines
SAN DIEGO—Kihara James, the Principal Accounting Officer at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), recently reported a series of stock transactions. The company, currently valued at $3.2 billion, has maintained strong financial health with an "GREAT" rating according to InvestingPro analysis. According to a Form 4 filed with the Securities and Exchange Commission, James sold 475 shares of common stock on February 24, 2025, at a price of $19.96 per share, totaling approximately $9,481. The transaction occurred near the stock's current trading level of $19.01, with the shares showing a 19% gain over the past six months
No big deal
NEU Price at posting:
$13.25 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)